Chemie Grünenthal

That a widely prescribed sedative caused catastrophic birth defects, and that the manufacturer suppressed and disputed the mounting evidence rather than withdrawing it.

Grünenthal marketed thalidomide from 1957 as safe in pregnancy, a claim never supported by adequate testing. As reports of phocomelia accumulated across Europe and Australia, the company disputed the link and pressured critics. Australian obstetrician William McBride and German paediatrician Widukind Lenz independently identified the cause in 1961.

Accounts are deliberately not collected here. This entry documents a historical case rather than a circulating remedy.

Roughly 10,000 children were born with severe limb malformations; around half survived infancy. Grünenthal did not apologise until 2012, fifty years on. The United States was largely spared because FDA reviewer Frances Kelsey refused approval, citing insufficient safety data, and withstood sustained pressure from the applicant. The disaster produced the 1962 Kefauver-Harris amendments requiring proof of efficacy and safety before marketing. This case is the strongest argument for pharmaceutical regulation and simultaneously the strongest evidence that manufacturers do sometimes lie.